NEWS SEARCH ANALYSIS INSIGHT

360° SearchNetwork Hot Spots Trends

Advanced Search Options >>

Saturday, November 21, 2009 9:01 AM

Immunotherapy

Type: Keyphrase

Name: Immunotherapy

First Reported 19 hours ago - Updated 8 hours ago - 5 Documents

Dendreon Corporation

Dendreon Corporation (DNDN) (JOBS) Receives FDA Acknowledgement of Complete Response, PDUFA Date Assigned as May 1, 2010

/PRNewswire-FirstCall via COMTEX/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE(R) (sipuleucel-T) ... [BioSpace - 8 hours ago]

Entities: Dendreon Corporation, Food and Drug Administration, complete response, Immunotherapy

First Reported 17 hours ago - Updated 16 hours ago - 2 Documents

Positive results from recently completed phase II clinical study of ToleroMune therapy announced

Study Identifies Optimal Treatment Approach for Late-Stage DevelopmentCircassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat ... [News-Medical.Net - 16 hours ago]

Entities: Circassia, clinical study, Immunotherapy, Placebo, Tolerance

First Reported 20 hours ago - Updated 20 hours ago - 1 Documents

Current and future immunotherapy in myasthenia gravis

Muscle & Nerve, 11/10/09 Relevance Score: 68%World Journal of Gastroenterology, 10/19/09 Relevance Score: 67%Neuro-Ophthalmology, 10/15/09 Relevance Score: 67%Annals of Thoracic Surgery, 10/13/09 Relevance Score: 66%Journal of Neuroimmunology, 10/05/09 ... [MDLinx - 20 hours ago]

Entities: Immunotherapy, Neuroimmunology, Thoracic Surgery

First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents

ALK Announces Landmark Asthma Prevention Trial

COPENHAGEN, DenmarkErkka Valovirta, GAP Lead Investigator & Chief Paediatrician and Paediatric Allergist, Turku, FinlandChildhood allergic rhinoconjunctivitis increases the risk for asthma development in later life by up to 7-fold. The progression of ... [Sys-Con Canada - 11/16/2009]

Entities: Immunotherapy, Pollen, Asthma

First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents (in Health)

Research and Markets: Dealmaking and Industry Outlook: Neurological Disease - Pharmaview...

BusinessWire - Research and Markets (http://www.researchandmarkets.com/research/63cb3f/dealmaking_and_ind) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Neurological Disease" to their offering.The ... [Forbes.com - 11/16/2009]

Entities: Neurological Disorders, Neurology, Protein, Receptor

First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents

ALK Announces Landmark Asthma Prevention Trial

ALK Today Announced the Initiation of its Landmark GRAZAX(R) Asthma Prevention (GAP) Trial.GAP will be the largest ever trial to investigate the asthma preventive effect of specific immunotherapy in children (5-12 years old) with allergic grass pollen ... [Individual.com - 11/17/2009]

Entities: Asthma, Pollen, Immunotherapy

First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents (in Health)

Strides Against Child Cancer

Promising news has been reported out of London regarding the fight against rare forms of child cancer. British scientists have developed new antibodies to help boost a child's immune system against some forms of cancer, including neuroblastoma.Neuroblastoma ... [Advance for Administrators of the Laboratory - 11/17/2009]

Entities: Neuroblastoma, Antibody, Tumor, Immune System

First Reported 11/18/2009 - Updated 11/18/2009 - 1 Documents

ALK Launches Largest-Ever Child Asthma Trial

ALK has announced the initiation of GAP, the largest-ever trial to investigate the effect of specific immunotherapy Grazax in children with allergic grass pollen rhinoconjunctivitis, commonly known as hay fever.The onset of allergic rhinoconjunctivitis ... [Pharmaceutical Technology - 11/18/2009]

Entities: Asthma, Immunotherapy, Pollen

First Reported 11/18/2009 - Updated 11/18/2009 - 1 Documents (in Biology)

Successful Immunotherapy of HCMV Disease Using Virus-Specific T Cells Expanded from an Allogeneic Stem Cell Transplant Recipient

American Journal of Transplantation ... [MDLinx - 11/18/2009]

Entities: allogeneic, Immunotherapy, Stem Cell

First Reported 11/02/2009 - Updated 11/02/2009 - 4 Documents

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

Dendreon Corporation (Nasdaq: DNDN) today announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company's lead investigational product, to the U.S. Food and Drug Administration ... [News-Medical.Net - 11/02/2009]

Entities: Immunotherapy, Dendreon Corporation, Food and Drug Administration, Metastatic, Prostate Cancer

First Reported 11/02/2009 - Updated 11/02/2009 - 3 Documents

Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of...

KENILWORTH, N.J.The study was a U.S. multicenter, randomized, placebo-controlled, double-blind, parallel-group clinical trial evaluating the efficacy of the grass sublingual tablet versus placebo in the treatment of grass pollen-induced rhinoconjunctivitis ... [Forbes.com - 11/02/2009]

Entities: Schering Plough Corporation, primary endpoint, Immunotherapy, Allergy, investigational

First Reported 10/29/2009 - Updated 10/30/2009 - 4 Documents (in Medicine)

Celldex cancer drug candidate returns positive news

Needham biotech Celldex Therapeutics Inc. received positive results from Phase 1 studies of its drug candidate, CDX-1307, intended to treat a number of cancers.CDX-1307 is designed for vaccine delivery using monoclonal antibodies against the cancer target, ... [Mass High Tech - 10/30/2009]

Entities: Avant Immunotherapeutics Inc, Immunotherapy, Monoclonal Antibodies

Quotes

...cat allergy therapy, and will prove invaluable as we progress our broader portfolio of ToleroMune products,' said Steve Harris, Circassia's CEO. "We are particularly pleased that the ToleroMune treatment achieved such a marked improvement in ocular symptoms, which can be a particular problem in cat allergy. As well as benefiting patients, this effect scientifically validates the ToleroMune approach and its novel focus on generating regulatory T cells to shut down this type of IgE-mediated allergic response." About Circassia

US FDA Panel Backs New Claim for Pfizer Inc. (PFE), Boehringer Ingelheim Corporation Lung Drug [BioSpace - 17 hours ago]

...that we have been able to move so fast with this first study of our LEAPS-H1N1 treatment," said Geert Kersten, CEL-SCI's Chief Executive Officer. "As we move forward, we hope that our investigational immunotherapy can be shown to modulate patients' immune responses to be effective without the cytokine storm that CEL-SCI's scientists believe may be responsible for so many deaths."

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospi ... [Yahoo! Canada - 11/18/2009]

Professor June said: "We are treating patients for the first time with an enhanced version of a natural T cell receptor designed to recognise and clear HIV. This is the first time an engineered T cell receptor will be given to patients with HIV infection. We will be treating patients currently well-controlled on HAART therapies in order to establish whether the engineered killer T cells containing the receptor are safe, and to identify a range of doses of the cells that can be safely administered. It is a truly an important day for T cell immunotherapy."

Worlds first engineered T cell receptor trial opens with new cellular therapy for HIV [Pharmacy Choice - 11/16/2009]

More Content

sort by: Date \| Relevance
Dendreon Corporation (DNDN) (JOBS) Receives FDA... [BioSpace - 8 hours ago]
Research and Markets: Strategies for Building E... [Forbes.com - 16 hours ago]
Dendreon Gets FDA Acceptance For Prostrate Canc... [RTTNews.com - 16 hours ago]
Positive results from recently completed phase ... [News-Medical.Net - 16 hours ago]
US FDA Panel Backs New Claim for Pfizer Inc. (P... [BioSpace - 17 hours ago]
Stocks to Watch: IMUC [Pharmacy Choice - 17 hours ago]
FDA acknowledges Dendreon's amended BLA for PRO... [News-Medical.Net - 18 hours ago]
Market Report -- In Play (DNDN) [Briefing.com via MSN Money - 18 hours ago]
Dendreon Corp. (DNDN) Receives U.S. FDA Complet... [Street Insider - 19 hours ago]
Dendreon Receives FDA Acknowledgement of Comple... [FinanzNachrichten.de - 19 hours ago]
Research and Markets: Strategies for Building E... [RBC Dain Rauscher - 19 hours ago]
Current and future immunotherapy in myasthenia ... [MDLinx - 20 hours ago]
Cancer Therapies - Global Market Opportunities [Pharmacy Choice - 11/19/2009]
ImmunoCellular Therapeutics Issues Letter to Sh... [Business Wire - 11/19/2009]
Research and Markets: Cancer Therapies - Global... [Business Wire UK - 11/19/2009]
Allogeneic Blood Stem Cell Transplants Using Le... [Cancer Consultants - 11/19/2009]
CEL-SCI Announces Start of First Clinical Study... [Yahoo! Canada - 11/18/2009]
Radiation Rx prevents melanoma’s invasion of ly... [Cancernetwork.com - 11/18/2009]
Immune system activated in schizophrenia [Genetic Engineering News - 11/18/2009]
CEL-SCI Announces Start of First Clinical Study of [PR Newswire via MSN Money - 11/18/2009]
Successful Immunotherapy of HCMV Disease Using ... [MDLinx - 11/18/2009]
ALK Launches Largest-Ever Child Asthma Trial [Pharmaceutical Technology - 11/18/2009]
Strides Against Child Cancer [Advance for Administrators of the Laboratory - 11/17/2009]
BioSante Pharmaceuticals to Present at the Laza... [Yahoo! Canada - 11/17/2009]
BioSante Pharmaceuticals to Present at the Laza... [Business Wire UK - 11/17/2009]
BioSante Pharmaceuticals to Present at the Laza... [Business Wire - 11/17/2009]
ALK Announces Landmark Asthma Prevention Trial [Individual.com - 11/17/2009]
'Diabetes increasing at alarming rate in Kuwait' [Arab Times - 11/17/2009]
BioSante Pharmaceuticals Comments on Boehringer... [Zibb - 11/16/2009]
Preclinical and Phase 1 Drugs in Development fo... [Retinal Physician - 11/16/2009]

Blogs

sort by: Date \| Relevance
An envious fever of pale and bloodless emulatio... [ScienceBlogs : Combined Feed - 10/01/2009] Fever is a fascinating phenomenon. The biochemistry and physiology of it is fairly well understood (sort of), but historically and presently, it is endowed with ...
Dendreon Investors Counting on FDA Approval of ... [Biotech Sector and Stocks Analysis from Seeking ... - 09/28/2009] Zacks.com submits: Dendreon Corporation ((DNDN) - Analyst Report) is likely to become the first company to receive approval from the U.S. Food and Drug Administration ...
Michael Milken, 60,000 Deaths, and the Story of... [Deep Capture: exposing the crime of naked short ... - 09/15/2009] During the past few weeks we have serialized a 30,000 word story about a network of market miscreants that includes disreputable financial analysts, prominent financial ...
Small Cap Stocks Battling Brain Cancer [Biotech Sector and Stocks Analysis from Seeking ... - 09/07/2009] Mike Havrilla submits:Each year nearly 20,000 people in the U.S. are diagnosed with primary brain cancers (with a similar number in Europe), according to NCI/NIH ...
Mentor Capital: Risk Mitigated Call Option on C... [Biotech Sector and Stocks Analysis from Seeking ... - 08/30/2009] Mike Havrilla submits:The stock research section of BioMedReports.com has been updated to include my 8-page report for Mentor Capital (MNTR.PK), which is current ...

Audio/Video

sort by: Date \| Relevance
Dr Juliet Gray and Professor Martin Glennie - n... [Cancer Research UK - YouTube Channel - 10/06/2009]
Immunotherapies [BIO Channel - YouTube - 07/07/2008]

Change Password

Log in to Silobreaker

Advanced Search Options

Immunotherapy